Which psychotropic medications are associated with tachycardia?

Psychotropic Medications That Cause Tachycardia

Multiple classes of psychotropic medications are associated with tachycardia, with antipsychotics (both typical and atypical) and tricyclic antidepressants posing the highest risk through anticholinergic and alpha-1 adrenergic blockade mechanisms.

High-Risk Medication Classes

Antipsychotic Medications

Both first-generation (typical) and second-generation (atypical) antipsychotics commonly cause tachycardia 1. In psychiatric inpatients experiencing severe tachycardia (heart rate ≥130 bpm), the use of atypical antipsychotics was associated with a 4-fold increased risk (OR: 4.09,95% CI: 1.64-10.2) after adjusting for confounders 2. This effect occurs through:

• Anticholinergic blockade - reduces parasympathetic tone
• Alpha-1 adrenergic receptor blockade - causes reflex tachycardia secondary to hypotension 3

Among antipsychotics, thioridazine carries particularly high cardiac risk, having been implicated in ventricular tachycardia cases, including one fatal case in a 35-year-old woman 4. Chlorpromazine has also caused supraventricular tachycardia 4.

Tricyclic Antidepressants (TCAs)

TCAs produce significant tachycardia through anticholinergic effects and are associated with increased cardiac arrest risk (OR = 1.69) 1. Amitriptyline and nortriptyline have documented cases of serious cardiac arrhythmias 4. The mean age of affected patients was 67 years, though cardiac complications can occur even in younger patients without pre-existing heart disease 4.

SSRIs and SNRIs

While generally safer than TCAs, SSRIs are associated with modest increased cardiac arrest risk (OR = 1.21) 1. Notably, SNRIs showed no significant association with cardiac arrest in registry studies 1, making them a potentially safer alternative when tachycardia is a concern.

Methadone

Methadone causes pronounced QT prolongation and has multiple documented cases of Torsades de Pointes 1. Baseline ECG is recommended, with follow-up ECGs when daily doses exceed 100-120 mg 1.

Mechanism of Tachycardia

The primary mechanisms include:

1. Anticholinergic effects - Direct reduction of parasympathetic tone
2. Alpha-1 receptor blockade - Causes postural hypotension triggering compensatory reflex tachycardia 3
3. QT prolongation - Can lead to ventricular arrhythmias including ventricular tachycardia 1

Risk Stratification

Highest risk patients include:

• Elderly patients (particularly >60 years) 1
• Those with pre-existing cardiovascular disease 3, 5
• Patients on multiple QT-prolonging medications 1
• Those with electrolyte disturbances 1
• Inherited cardiac ion channel disorders 3

Clinical Management Algorithm

Before initiating Class B or B psychotropic medications* (those with QT prolongation risk) 1:

1. Obtain baseline ECG - assess for QT prolongation, conduction disorders, structural heart disease
2. Check electrolytes - particularly potassium and magnesium
3. Review medication list - identify other QT-prolonging drugs or CYP inhibitors
4. Assess cardiac history - chest pain, palpitations, syncope, family history of sudden cardiac death

During treatment 1:

• Re-evaluate ECG within 1-2 weeks after initiation or significant dose increase (at steady-state)
• Discontinue medication if QTc >500 ms or increases >60 ms from baseline 1
• Monitor for symptoms: palpitations, dizziness, syncope

Safer Alternatives

When tachycardia is a concern:

• Prefer SNRIs over TCAs or SSRIs for depression (no cardiac arrest association) 1
• Choose buprenorphine over methadone for opioid addiction (far less QT prolongation) 1
• Select Class A psychotropics when possible (no QT prolongation risk) 1
• Benzodiazepines are generally cardiac-safe, even in patients with myocardial infarction 1, 5

Critical Pitfalls to Avoid

• Do not assume atypical antipsychotics are safer than typical antipsychotics - registry data shows similar dose-dependent sudden cardiac death risk (incidence-rate ratios 1.59-2.86 vs 1.31-2.42) 1
• Young patients without heart disease can still develop life-threatening arrhythmias - five of eight patients with major arrhythmias in one series were ≤50 years old 4
• Sinus tachycardia was the most common rhythm in severe tachycardia cases 2, but ventricular tachycardia remains a serious risk with certain agents 4